Konference: 2015 20th Congress of the European Hematology Association - účast ČR
Kategorie: Myeloproliferativní nemoci
Téma: ePoster
Číslo abstraktu: E1238
Autoři: Doc. MUDr.,Mgr. Jiří Minařík, PhD; Dr., Ing. Eva Kriegová; Mgr. Petra Schneiderová; Mgr. Jana Zapletalová; MUDr. Petra Puščiznová; MUDr. Jan Hrbek; MUDr. Zuzana Heřmanová, Ph.D.; MUDr. Tomáš Pika; Doc.MUDr. Jaroslav Bačovský, CSc.; Prof. MUDr. Miroslav Heřman, Ph.D.; Prof.MUDr. Vlastimil Ščudla, CSc.
Background
The assessment of prognostic factors in cancer is vital for correct
stratification and targeted therapy. In multiple myeloma, both
tumor cells and bone marrow microenvironment play an important role
in pathogenesis, and take part on the development and the extent of
myeloma bone disease (MBD).
Aims
The aim of our project was to address the utility of
Proximity Extention
ImmunoAssay technique (PEA) in patients with
monoclonal gammopathies instead of standard ELISA techniques in the
assessment of tumor microenvironment parameters.
Methods
We assessed 92 cancer-related parameters from the Oncology I
96x96 protein biomarker panel (Olink, Uppsala, Sweden).
The parameters are known to be altered in various cancer types and
are related to angiogenesis, cell-cell signaling, growth control
and inflammation. Both sera and bone marrow samples were acquired
from 30 patients with monoclonal gammopathies - 25 patients with
multiple myeloma (MM) and 5 individuals with monoclonal gammopathy
of undetermined significance (MGUS) taken at the time of
diagnosis.PEA is a sensitive and specific alternative of ELISA
methods. For each sample there are two different antibody probes
labeled with A- and B-oligonucleotides. Proximity of the
oligonucleotide chains to the binding site leads to PCR
amplification of the signal with specific primers. For statistical
estimation we used Mann-Whitney U-test, Kruskal-Wallis test and
Spearman correlation analysis at p?0.05 and Principal Component
Analysis (GenEx, SSPS).
Results
In 3 patients the data did not pass the quality control. In the
rest 27 individuals we analysed parallelly bone marrow and sera
analytes. In 58 analytes the levels in bone marrow and serum were
significantly different, with up to 38 fold difference (over 5 log
scale), the rest 34 analytes had similar levels in both bone marrow
and sera. Out of the whole panel, 9 analytes were significally
different when comparing individuals with or without the presence
of renal impairment. We found 19 proteins that significantly
differed between MGUS and MM in both serum and bone marrow. There
were several perspective candidate biomarkers correlating with
disease stage, extent of myeloma bone disease, M-protein type and
therapeutic outcome, such as tartrate resistant
alkalinephosphatase-5 (TRAP-5), matrix metalloproteinase 1 (MMP-1),
tumor necrosis factor (TNF), transforming growth factor alpha
(TGF-α), Fas antigen ligand (FasL), Fms-related tyrosine kinase 3
ligand (Flt3-L) or epithelial cell-adhesion molecule
(Ep-CAM).
Summary
Proximity ImmunoAssay is a very sensitive technique enabling
parallel assessment of several analytes. Unlike ELISA, it has many
fold larger dynamic range, and is suitable for analyte levels
beyond the calibration curve. Out of the Oncology panel, 9
parameters were influenced by renal impairment. Despite limited
number of patients, we could trace several potential candidates for
the assessment of MM pathogenesis as well as for the extent
of myeloma bone disease.
Supported by the grant NT14393
Datum přednesení příspěvku: 12. 6. 2015